Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p.... |
Good MorningStocks ended the day driven by big tech and bank headlines. NVIDIA’s CES showcase and RTX 60-Series debut helped the chip giant briefly push market value above $4.76 trillion before cooling back toward $4.5–$4.6 trillion, keeping AI enthusiasm at the market’s center. JPMorgan reported a 9% adjusted profit rise in Q4—$13.03 billion, or $4.63 a share—though results were trimmed by a one-time 60-cent charge tied to its Apple Card acquisition and $2.2 billion added to loan-loss reserves. December inflation was mostly unchanged while core prices cooled slightly, a development markets watch closely for Fed policy signals.
Policy risk and regulation crept into market thinking. Nine central bankers voiced full solidarity with Fed Chair Powell amid President Trump’s escalating confrontations with the Fed, and Wall Street executives warned that attacks on regulators and the credit card industry could unsettle markets. Microsoft’s Brad Smith pressed lawmakers for Big Tech to shoulder the costs of sprawling AI data centers, signaling potential regulatory and cost pressures for cloud and chip providers. Featured: The 7 Stocks Quietly Gaining Attention Right Now (Ad) 
| Markets | |
Volatility is returning to Wall Street, signaling a potential fracture in the bull market sentiment that defined the previous year. Recent trading sessions have seen Nasdaq futures face noticeable downward pressure, a stark contrast to the smooth sailing investors grew accustomed to in 2025. The p... Read the Full Story |
| From Our Partners | | A drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years.
While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million.
One company controls the entire supply chain behind this discovery. | | See the ticker behind this Grand Canyon energy breakthrough now |
| Healthcare | |
In the last few months of 2025, shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) went on an undeniable hot streak. From the beginning of August 2025 to the end of the year, the stock rose 41%. Optimism surrounding Lilly’s current and developmental weight loss and diabetes t... Read the Full Story |
| Finance | |
A convergence of factors has JPMorgan Chase & Company (NYSE: JPM) stock poised to rally in 2026. The stock surged in 2025 and could advance as much as 20% by year’s end. Below, we'll examine what's driving the JPM market and why the financial stock could see the $400 level this year.
Ja... Read the Full Story |
| From Our Partners | | Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies.
Dr. Mark Skousen, who met Musk in person and called the SpaceX listing months early, says he has identified all three targets in what he calls Elon's $2.1 Trillion Hit List.
See the three companies before the rumors become headlines. | | Get the details on all three companies now |
| Consumer Discretionary | |
Shares of tech giant Amazon.com Inc (NASDAQ: AMZN) surged more than 10% last week, starting what looks like what could be a decisive run toward November's all-time high. The move hasn't come out of the blue. For months now, the stock has been carving out a steady series of higher lows, quietly b... Read the Full Story |
| Technology | |
In the middle of January 2026, the two largest forces in mobile computing effectively called a truce in the war for artificial intelligence (AI) dominance. After months of speculation and market volatility, Apple Inc. (NASDAQ: AAPL) and Alphabet Inc. (NASDAQ: GOOG) formalized a strategic partnersh... Read the Full Story |
| From Our Partners | | AI is expanding beyond software into robots, factories, vehicles, and intelligent machines. That shift could create a new group of market leaders before most investors notice.
A complimentary report, 5 Stocks Powering the Physical AI Revolution, identifies five companies positioned at the center of this shift, along with the technologies, growth drivers, and risks to understand. | | Get your free copy before physical AI becomes Wall Street's next crowded trade |
| Finance | |
The market reaction in the finance and fintech sectors on Jan. 12, 2026, was not a panic sell-off. It was a precise, calculated sorting event. Following the Trump administration's announcement of a proposed 10% cap on credit card interest rates, the financial sector fractured. While the headlines ... Read the Full Story |
| Technology | |
NVIDIA (NASDAQ: NVDA) has achieved a level of dominance in the stock market that defies historical comparison. The chip giant's market capitalization briefly peaked above $4.76 trillion following its dominant presentation at CES 2026, which featured the debut of its new consumer-focused RTX 60-Ser... Read the Full Story |
| Consumer Discretionary | |
After gaining just 6% last year, consumer discretionary stocks entered 2026 looking for some relief from the fallout from tariffs, margin compression, and a weakening labor market.
But for automotive stocks, the situation was a little different. According to Autoweek, U.S. auto sales were strong... Read the Full Story |
| Markets | |
In the face of inflation, changing interest rates, and broader market instability, income-generating exchange-traded funds (ETFs) may be a strong defensive choice for investors in 2026. These funds offer the benefit of steady distributions by focusing on dividend-paying stocks, on bonds, or on oth... Read the Full Story |
| Technology | |
AI is a fast-growing market whose outlook has yet to be fully reflected in its stock prices. While it's hard to say for certain which AI infrastructure, model builder, or application will stand the test of time, it is certain that AI and the cloud are here to stay.
Many organizations use multiple... Read the Full Story |
| Wednesday's Early Bird Stock Of The Day Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. | Should I Buy Pfizer Stock? PFE Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Pfizer was last updated on Thursday, October 15, 2026 at 6:34 PM.
Pfizer Bull Case -
Pfizer Inc. offers an attractive income stream with a dividend yield of 6.06%, which is significantly higher than the 10-year Treasury note, making it a compelling option for income-focused investors seeking to outperform traditional bond yields.
-
The stock is trading at $29.47, approaching its 52-week high of $29.88, indicating strong recent momentum and potential for further upside as the company presents data from over 50 abstracts at IDWeek 2026, including updates on its Lyme vaccine and next-generation pneumococcal vaccine.
-
Pfizer Inc. has demonstrated strong financial performance, beating analysts' consensus estimates for earnings per share in the most recent quarter with $0.77 compared to the expected $0.68, and revenue of $15.03 billion, which exceeded the consensus estimate of $14.40 billion.
-
The company has a low beta of 0.32, suggesting that its stock price is less volatile than the overall market, which can be beneficial for investors looking to reduce portfolio risk while still participating in the growth of the pharmaceutical sector.
-
Pfizer Inc. has entered a research collaboration and licensing agreement with Enodia Therapeutics to discover and develop Sec61-targeting small molecules, adding another external innovation program to its pipeline and potentially expanding its future revenue opportunities.
Pfizer Bear Case -
The consensus recommendation from 21 brokerages is "Hold," with an average 1-year price objective of $28.72, which is below the current stock price of $29.47, suggesting limited upside potential in the near term.
-
Pfizer Inc. has a high payout ratio of 226.32%, which raises concerns about the sustainability of its dividend, as the company is paying out more in dividends than it is earning in profits.
-
The company's outlook remains dependent on pipeline execution and replacing pandemic-related revenue declines, which could pose challenges to achieving its FY 2026 guidance of $2.80-$3.00 EPS.
-
Several analyst price targets cluster between $25 and $28, which is below the current share price, indicating that some analysts believe the stock is overvalued and could face downward pressure.
-
Pfizer Inc. has a debt-to-equity ratio of 0.71, which, while not excessively high, still represents a significant level of debt that could impact the company's financial flexibility and ability to invest in new projects.
| | View Today's Stock Pick |
|
| |
|
|
